Inspire Medical Systems Reports Positive Clinical Outcomes for Inspire V System

By Ahmed Jameison • Saturday, October 11 12:12 • Permanent Link

Inspire Medical Systems, Inc. (NYSE: INSP) has recently published Inspire V clinical outcomes data from its Singapore clinical study as well as the company’s limited market release in the United States. The data, which were presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical Sleep Society (ISSS) meetings, showcase the advancements made with the Inspire V system.

In the Singapore study, 44 patients received the Inspire V system and were followed for six months post-implant. The results demonstrated a 20% reduction in surgical times compared to the previous generation, with 100% of the procedures completed successfully. The Inspire V system also showed superior respiratory sensing and increased patient adherence, with an average usage of 5.5±1.7 hours per night at a mean of 246 days post-implant. Additionally, the median reduction in the apnea hypopnea index (AHI) was notable, decreasing from 34.4 events/hour at baseline to 8.3 events/hour at month six for the 37 patients who completed this clinical visit.

In the limited market release evaluation in the United States, 101 patients underwent successful Inspire V system procedures with no serious adverse events. At the 60-day check, all 101 patients were using their therapy, with an average usage of 6.8 hours per night. Subsequent sleep study data for the first 34 patients demonstrated a median reduction in AHI from 30 to 4.5 events/hour, indicating therapeutic values. The average amplitude of stimulation remained steady at 1.7 volts, and therapy adherence remained consistent at 6.7 hours per night.

The company also provided single-site results from two leading centers in the U.S. Dr. Phil Huyett from the Massachusetts Eye and Ear Infirmary reported an average surgical implant time of 34.5 minutes, while Dr. Nic Beckmann at Colorado ENT and Allergy reported an increase in implant volume with the Inspire V system due to shorter procedure times.

The market has reacted to these announcements by moving the company's shares 2.04% to a price of $80.14. For the full picture, make sure to review Inspire Medical Systems's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.